Palatin Technologies, Inc. today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.
Exicure, Inc. today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of directors (the “Board”).
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors Read More »
Seres Therapeutics, Inc. today announced that it has entered into a new $250 million senior secured debt facility (“Term Loan Facility”) provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree Read More »
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance.
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance Read More »
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which, among other things, HWEL Holdings Corp., a newly formed wholly-owned subsidiary of Healthwell (“Pubco”), has agreed to acquire Starton and become a publicly traded company (the “Transaction”).
NeoDynamics, Inc. announced the U.S. availability of NEONAVIA, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.
Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May.
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update.
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 Read More »
We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC Read More »
Seres Therapeutics, Inc. and Nestlé Health Science announced the U.S. Food and Drug Administration approval of VOWSTTM, formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI.
